SCHEMBL9944320

SCHEMBL9944320

CCC(CC)Oc1cc(C(=O)Nc2ccc(C=O)c(C)c2)cc(Cl)c1OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 3/20 0.47
TAS1R1 Q7RTX1 3/20 0.47
TAS1R2 Q8TE23 3/20 0.47
MAPT P10636 7/20 0.46
LMNA P02545 2/20 0.43
GAA P10253 2/20 0.43
MEN1 O00255 5/20 0.42
KMT2A Q03164 5/20 0.42
POLB P06746 4/20 0.42
ALDH1A1 P00352 2/20 0.41
HPGD P15428 1/20 0.41
PLAU P00749 1/20 0.41
USP2 O75604 1/20 0.40
MCL1 Q07820 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9944353 0.90 TAS1R3 (0.50) TAS1R3TAS1R1TAS1R2MAPTLMNA
SCHEMBL9944237 0.86 TAS1R3 (0.48) TAS1R3TAS1R1TAS1R2MAPTLMNA
SCHEMBL9944346 0.86 TAS1R3 (0.53) TAS1R3TAS1R1TAS1R2MAPTLMNA
SCHEMBL1458204 0.85 TAS1R3 (0.47) TAS1R3TAS1R1TAS1R2MAPTLMNA
SCHEMBL9944347 0.83 MAPT (0.45) MAPTLMNAGAAMEN1KMT2A
SCHEMBL9944331 0.83 RAB9A (0.49) MAPTLMNAGAAMEN1KMT2A
SCHEMBL9944303 0.83 MEN1 (0.51) TAS1R3TAS1R1TAS1R2MAPTLMNA
SCHEMBL9944342 0.82 MAPT (0.49) MAPTLMNAGAAMEN1KMT2A
SCHEMBL1458138 0.82 TAS1R3 (0.55) TAS1R3TAS1R1TAS1R2MAPTLMNA
SCHEMBL9944236 0.82 TAS1R3 (0.55) TAS1R3TAS1R1TAS1R2MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use KING'S COLLEGE LONDON (GB) 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149737-A1 Therapeutic Aryl-Amido-Aryl Compounds and Their Use RARA, RARB, RARG TAS1R3 1123/4885TAS1R1 693/4885TAS1R2 808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.